We are live on ! Find out more
SCNI

Scinai Immunotherapeutics

1.13 USD
-0.09
7.38%
At close Updated Oct 7, 4:00 PM EDT
Pre-market
After hours
1.18
+0.05
4.42%
1 day
-7.38%
5 days
-18.71%
1 month
-33.53%
3 months
-56.2%
6 months
-80.21%
Year to date
-84.52%
1 year
-92.26%
5 years
-99.95%
10 years
-99.97%
 

About: Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.

Employees: 45

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 100%
Negative 0%
Neutral
PRNewsWire
16 days ago
Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement
Nasdaq confirms compliance with Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above $1.00; minimum bid price matter is closed JERUSALEM, Sept. 21, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.
Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement
Neutral
PRNewsWire
29 days ago
Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business
Following the conclusion of the PinCell option and license arrangements, Scinai concentrates resources on its NanoAb platform and CDMO commercial execution, without taking on additional PC111 funding commitments JERUSALEM, Sept. 8, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.
Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business
Neutral
Seeking Alpha
1 month ago
Scinai Immunotherapeutics Ltd. (SCNI) Q2 2026 Earnings Call Transcript
Scinai Immunotherapeutics Ltd. (SCNI) Q2 2026 Earnings Call Transcript
Scinai Immunotherapeutics Ltd. (SCNI) Q2 2026 Earnings Call Transcript
Neutral
PRNewsWire
1 month ago
Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum
Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDT JERUSALEM, Aug. 24, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd.
Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum
Neutral
PRNewsWire
1 month ago
Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration
Appointment strengthens operational infrastructure and supports integration and scale-up of Scinai's expanded CDMO platform. JERUSALEM, Aug. 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.
Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration
Neutral
PRNewsWire
3 months ago
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives
JERUSALEM, June 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating CDMO subsidiary, today reported financial results for the three months ended March 31, 2026 and provided a corporate update.
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives
Neutral
PRNewsWire
4 months ago
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
JERUSALEM, May 20, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd.
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
Neutral
PRNewsWire
4 months ago
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe
JERUSALEM, May 15, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company focused on inflammation and immunology, today announced that members of its leadership team will lead a strategic roundtable discussion at the 7th Dermatology Drug Development Summit Europe, taking place next week in Amsterdam, the Netherlands.
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe
Positive
Benzinga
5 months ago
Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today
Scinai Immunotherapeutics Ltd – ADR (NASDAQ:SCNI) shares are surging Friday morning after the company announced fresh financing tied to a private placement and warrant exercise, helping refocus attention on its near-term funding runway. Here's what investors need to know.
Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today
Neutral
PRNewsWire
5 months ago
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing
Financing led by institutional life sciences investor, with participation from new and existing investors Capital expected to support expansion of CDMO platform and advancement of customer programs JERUSALEM, April 24, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics and the owner of Scinai Biopharma Services Ltd.
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing
Price charts implemented using Lightweight Charts™